Abstract
Objectives
Since the external validation of severe acute respiratory syndrome coronavirus 2 antigen rapid diagnostic tests (SARS-CoV-2 RDT-Ags) is a necessary requisite before they can be introduced into routine clinical practice, this study reports the results of a real-world assessment of the clinical performance of the new COVID-VIRO ALL IN device.
Methods
The study population consisted in 165 outpatients (median age: 43 years, range: 14–68 years; 66.1% females) who had paired nasal and nasopharyngeal samples collected upon hospital presentation. The samples were concomitantly tested with the AAZ-LMB COVID-VIRO ALL IN SARS-CoV-2 RDT-Ag and with Cepheid Xpert Xpress SARS-CoV-2 real-time reverse transcription polymerase chain reaction (RT-PCR).
Results
The number of subjects with positive RT-PCR results (i.e., mean Ct value <45) was 116 (70.3%), 109 (66.1%) and 86 (52.1%) with mean Ct values <37 and <30, respectively. In all RT-PCR positive samples, COVID-VIRO ALL IN displayed 78.8% agreement, 0.698 sensitivity, 1.000 specificity, 0.583 negative predictive value (NPV) and 1.000 positive predictive value (PPV) compared to RT-PCR. The median Ct value of samples testing positive with COVID-VIRO ALL IN was significantly lower than those testing negative (22.8 vs. 32.2; p<0.001). In samples with high viral load (i.e., Ct value <30), COVID-VIRO ALL IN displayed 92.1% agreement, 0.895 sensitivity, 0.949 specificity, 0.983 NPV and 0.951 PPV compared to RT-PCR.
Conclusions
Although the diagnostic performance of COVID-VIRO ALL IN do not exactly match those of the manufacturer, its high NPV in high viral load samples would enable fast-track and rapid identification of highly contagious subjects.
Acknowledgments
The authors acknowledge the staff of the Service of Laboratory Medicine and the Medical Direction of the Pederzoli Hospital (Peschiera del Garda, Italy) for support and technical assistance.
-
Research funding: None declared.
-
Author contributions: All authors have accepted responsibility for the entire content of this manuscript and approved its submission.
-
Competing interests: Authors state no conflict of interest.
-
Informed consent: Informed consent was obtained from all individuals included in this study.
-
Ethical approval: The investigation was conducted in accordance with the Declaration of Helsinki, under the terms of relevant local legislation, and was part of broader study protocol cleared by the Ethical Committee of the Provinces of Verona and Rovigo (971CESC; Approved July 25, 2016).
References
1. Lippi, G, Sanchis-Gomar, F, Henry, BM. Coronavirus disease 2019 (COVID-19): the portrait of a perfect storm. Ann Transl Med 2020;8:497. https://doi.org/10.21037/atm.2020.03.157.Search in Google Scholar PubMed PubMed Central
2. World Health Organization. WHO coronavirus (COVID-19) dashboard. Available from: https://covid19.who.int/ [Accessed 15 Dec 2022].Search in Google Scholar
3. Lippi, G, Plebani, M. Laboratory medicine resilience during coronavirus disease 2019 (COVID-19) pandemic. Adv Lab Med 2020;1:20200035. https://doi.org/10.5935/1676-2444.20200035.Search in Google Scholar
4. World Health Organization. Public health surveillance for COVID-19: interim guidance – interim guidance. Available from: https://www.who.int/publications/i/item/WHO-2019-nCoV-SurveillanceGuidance-2022.2 [Accessed 15 Dec 2022].Search in Google Scholar
5. Lippi, G, Favresse, J, Gromiha, MM, SoRelle, JA, Plebani, M, Henry, BM. Ad interim recommendations for diagnosing SARS-CoV-2 infection by the IFCC SARS-CoV-2 variants working group. Clin Chem Lab Med 2022;60:975–81. https://doi.org/10.1515/cclm-2022-0345.Search in Google Scholar PubMed
6. Zhen, W, Smith, E, Manji, R, Schron, D, Berry, GJ. Clinical evaluation of three sample-to-answer platforms for detection of SARS-CoV-2. J Clin Microbiol 2020;58:e00783–20. https://doi.org/10.1128/JCM.00783-20.Search in Google Scholar PubMed PubMed Central
7. Hong, KH, Lee, J, Kim, SY, Oh, Y, Cho, HW, Lee, H. Comparison of the clinical performance of the point-of-care STANDARD M10 SARS-CoV-2 and Xpert Xpress SARS-CoV-2 assays. Ann Lab Med 2023;43:111–3. https://doi.org/10.3343/alm.2023.43.1.111.Search in Google Scholar PubMed PubMed Central
8. US Food and Drug Administration. SARS-CoV-2 viral mutations: impact on COVID-19 tests. Available from: https://www.fda.gov/medical-devices/coronavirus-covid-19-and-medical-devices/sars-cov-2-viral-mutations-impact-covid-19-tests [Accessed 15 Dec 2022].Search in Google Scholar
9. Salvagno, GL, Henry, BM, Bongiovanni, G, De Nitto, S, Pighi, L, Lippi, G. Positivization time of a COVID-19 rapid antigen self-test predicts SARS-CoV-2 viral load: a proof of concept. Clin Chem Lab Med 2022. https://doi.org/10.1515/cclm-2022-0873.Search in Google Scholar PubMed
10. Istituto Superiore di Sanità. Sorveglianza integrata COVID-19. Available from: https://www.epicentro.iss.it/coronavirus/sars-cov-2-sorveglianza-dati [Accessed 15 Dec 2022].Search in Google Scholar
11. AAZ-LMB. Instruction leaflet. Available from: https://www.autotest-sante.com/medias/fichiers/notice_autotest_covid_viro_all_in_en.pdf [Accessed 15 Dec 2022].Search in Google Scholar
12. Mattiuzzi, C, Henry, BM, Lippi, G. Regional association between mean air temperature and case numbers of multiple SARS-CoV-2 lineages throughout the pandemic. Viruses 2022;14:1913. https://doi.org/10.3390/v14091913.Search in Google Scholar PubMed PubMed Central
13. Mitchell, EP. Influenza, respiratory syncytial Virus and COVID-19: three respiratory killers at risk to patients. J Natl Med Assoc 2022;114:551–2. https://doi.org/10.1016/j.jnma.2022.12.010.Search in Google Scholar PubMed PubMed Central
14. Cohen, J. Will viral interference hold off the tripledemic? Science 2022;378:814–5. https://doi.org/10.1126/science.adf8989.Search in Google Scholar PubMed
15. Lippi, G. Brief update on coronavirus disease 2019 (COVID-19) diagnostics. Adv Lab Med 2020;1:20200099. https://doi.org/10.1515/almed-2020-0099.Search in Google Scholar PubMed PubMed Central
16. Mattiuzzi, C, Henry, BM, Lippi, G. Making sense of rapid antigen testing in severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) diagnostics. Diagnosis (Berl) 2021;8:27–31. https://doi.org/10.1515/dx-2020-0131.Search in Google Scholar PubMed
17. Prazuck, T, Gravier, A, Pires-Roteira, D, Theillay, A, Pallay, S, Colin, M, et al.. Evaluation of a new “all in one” SARS-CoV-2 antigen-detecting rapid diagnostic test and self-test: diagnostic performance and usability in child and adult populations. J Med Virol 2022;94:4097–106. https://doi.org/10.1002/jmv.27812.Search in Google Scholar PubMed PubMed Central
18. Dinnes, J, Sharma, P, Berhane, S, van Wyk, SS, Nyaaba, N, Domen, J, et al.. Cochrane COVID-19 Diagnostic Test Accuracy Group. Rapid, point-of-care antigen tests for diagnosis of SARS-CoV-2 infection. Cochrane Database Syst Rev 2022;7:CD013705. https://doi.org/10.1002/14651858.CD013705.pub3.Search in Google Scholar PubMed PubMed Central
19. Fragkou, PC, Moschopoulos, CD, Dimopoulou, D, Ong, DSY, Dimopoulou, K, Nelson, PP, et al.. European Society of Clinical Microbiology and Infection Study Group for Respiratory Viruses. Performance of point-of care molecular and antigen-based tests for SARS-CoV-2: a living systematic review and meta-analysis. Clin Microbiol Infect 2022. S1198-743X(22)00542-0. https://doi.org/10.1016/j.cmi.2022.10.028.Search in Google Scholar PubMed PubMed Central
20. Lippi, G, Henry, BM, Plebani, M, Adeli, K. Systematic review of diagnostic accuracy of DiaSorin liaison SARS-CoV-2 antigen immunoassay. EJIFCC 2022;33:94–104.Search in Google Scholar
21. Lippi, G, Henry, BM, Adeli, K. Diagnostic performance of the fully automated Roche Elecsys SARS-CoV-2 antigen electrochemiluminescence immunoassay: a pooled analysis. Clin Chem Lab Med 2022;60:655–61. https://doi.org/10.1515/cclm-2022-0053.Search in Google Scholar PubMed
22. Lippi, G, Henry, BM, Adeli, K, Plebani, M. Fujirebio Lumipulse SARS-CoV-2 antigen immunoassay: pooled analysis of diagnostic accuracy. Diagnosis (Berl) 2022;9:149–56. https://doi.org/10.1515/dx-2022-0021.Search in Google Scholar PubMed
23. Ford, L, Lee, C, Pray, IW, Cole, D, Bigouette, JP, Abedi, GR, et al., CDC COVID-19 Surge Laboratory Group. Epidemiologic characteristics associated with severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) antigen-based test results, real-time reverse transcription polymerase chain reaction (rRT-PCR) cycle threshold values, subgenomic RNA, and viral culture results from University testing. Clin Infect Dis 2021;73:e1348–55. https://doi.org/10.1093/cid/ciab303.Search in Google Scholar PubMed PubMed Central
24. Kessler, HH, Prüller, F, Hardt, M, Stelzl, E, Föderl-Höbenreich, E, Pailer, S, et al.. Identification of contagious SARS-CoV-2 infected individuals by roche’s rapid antigen test. Clin Chem Lab Med 2022;60:778–85. https://doi.org/10.1515/cclm-2021-1276.Search in Google Scholar PubMed
25. Zhao, Y, Zhao, S, Guo, Z, Yuan, Z, Ran, J, Wu, L, et al.. Differences in the superspreading potentials of COVID-19 across contact settings. BMC Infect Dis 2022;22:936. https://doi.org/10.1186/s12879-022-07928-9.Search in Google Scholar PubMed PubMed Central
26. Lippi, G, Henry, BM, Plebani, M. An overview of the most important preanalytical factors influencing the clinical performance of SARS-CoV-2 antigen rapid diagnostic tests (Ag-RDTs). Clin Chem Lab Med 2022;61:196–204. https://doi.org/10.1515/cclm-2022-1058.Search in Google Scholar PubMed
27. Salvagno, GL, Henry, BM, De Nitto, S, Pighi, L, Lippi, G. Correlation between time to positive result of SARS-CoV-2 rapid antigen self-test and viral antigen concentration. EJIFCC 2022;33:309–16.10.1515/cclm-2022-0873Search in Google Scholar PubMed
© 2023 Walter de Gruyter GmbH, Berlin/Boston
